MyFinsight
Home
Blog
About
Redemption of term deposits
$64,940K
(144.52%↑ Y/Y)
Decrease in r&d benefit
receivable
-$12,924K
(-103.75%↓ Y/Y)
Proceeds from issue of
ordinary shares
$2K
(-86.67%↓ Y/Y)
Decrease in trade and
other payables
$2,204K
(165.11%↑ Y/Y)
Share-based compensation
expense
$1,308K
(-76.75%↓ Y/Y)
Net foreign
exchange impacts
-$178K
(98.48%↑ Y/Y)
Depreciation expense
$73K
(-52.60%↓ Y/Y)
Amortization expense
$35K
(-73.48%↓ Y/Y)
Income tax expense
$1K
(-90.00%↓ Y/Y)
Net cash provided
by/(used in) investing...
$64,940K
(241.35%↑ Y/Y)
Net cash used in
operations
$1,518K
(104.45%↑ Y/Y)
Net cash provided by
financing activities
$2K
(-86.67%↓ Y/Y)
Canceled cashflow
$15,205K
Increase/(decrease) in cash and cash
equivalents
$66,460K
(183.05%↑ Y/Y)
Net loss
-$12,268K
(78.05%↑ Y/Y)
(increase)/decrease in other current
assets
$2,329K
(196.00%↑ Y/Y)
Other income, net
$584K
(-68.09%↓ Y/Y)
Decrease in operating
lease liabilities
-$24K
(80.95%↑ Y/Y)
Back
Back
Cash Flow
Silence Therapeutics plc (SLN)
Silence Therapeutics plc (SLN)
source: myfinsight.com